Contemporary issues and lifetime management in patients underwent transcatheter aortic valve replacement.
Kensuke MatsushitaOlivier MorelPatrick OhlmannPublished in: Cardiovascular intervention and therapeutics (2023)
Latest clinical trials have indicated favorable outcomes following transcatheter aortic valve replacement (TAVR) in low surgical risk patients with severe aortic stenosis. However, there are unanswered questions particularly in younger patients with longer life expectancy. While current evidence are limited to short duration of clinical follow-up, there are certain factors which may impair patients clinical outcomes and quality-of-life at long-term. Contemporary issues in the current TAVR era include prosthesis-patient mismatch, heart failure hospitalization, subclinical thrombosis, future coronary access, and valve durability. In this review, the authors review available evidence and discuss each remaining issues and theoretical treatment strategies in lifetime management of TAVR patients.
Keyphrases
- aortic stenosis
- transcatheter aortic valve replacement
- ejection fraction
- aortic valve
- aortic valve replacement
- transcatheter aortic valve implantation
- end stage renal disease
- heart failure
- clinical trial
- newly diagnosed
- left ventricular
- chronic kidney disease
- coronary artery disease
- prognostic factors
- mitral valve
- phase iii